OA10.01 Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.288
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Different Mutational Characteristics of the Subsets of EGFR-tyrosine Kinase Inhibitor Sensitizing Mutation-Positive Lung Adenocarcinoma

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

PCN134 Patient Preferences for Non-Small Cell Lung Cancer (NSCLC) Treatments

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor

OncoTargets and Therapy
OncologyPharmacology
2016English

Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Impressive Response to Tyrosine Kinase Inhibitors in a Patient With Respiratory Failure for EGFR -Mutated Metastatic Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

PCC0208027, a Novel Tyrosine Kinase Inhibitor, Inhibits Tumor Growth of NSCLC by Targeting EGFR and HER2 Aberrations

Scientific Reports
Multidisciplinary
2019English

P3.01-75 RELAY+, an Exploratory Study of Gefitinib With Ramucirumab in Untreated Patients With EGFR Mutation-Positive Metastatic NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management
2020English

Association of Exon 19 and 21 EGFR Mutation Patterns With Treatment Outcome After First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy